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Quality of lifeAbstract Introduction: Older patients with early breast cancer (EBC) derive modest survival
benefit from chemotherapy but have increased toxicity risk. Data on the impact of chemo-
therapy for EBC on quality of life in older patients are limited, but this is a key determinant
of treatment acceptance. We aimed to investigate its effect on quality of life in older patients
enrolled in the Bridging the Age Gap study.
Materials and methods: A prospective, multicentre, observational study of EBC patients 70
years old was conducted in 2013e2018 at 56 UK hospitals. Demographics, patient, tumour
characteristics, treatments and adverse events were recorded. Quality of life was assessed using
the European Organisation for Research and Treatment of Cancer Quality-of-Life Question-
naires (EORTC-QLQ) C30, BR23 and ELD 15 plus the Euroqol-5D (eq-5d) over 24 months
and analysed at each time point using baseline adjusted linear regression analysis and propen-
sity score-matching.
Results: Three thousand and four hundred sixteen patients were enrolled in the study; 1520
patients undergoing surgery and who had high-risk EBC were included in this analysis. 376/
1520 (24.7%) received chemotherapy. At 6 months, chemotherapy had a significant negative
impact in several EORTC-QLQ-C30 domains, including global health score, physical, role, so-
cial functioning, cognition, fatigue, nausea/vomiting, dyspnoea, appetite loss, diarrhoea and
constipation. Similar trends were documented on other scales (EORTC-QLQ-BR23,
EORTC-QLQ-ELD15 and EQ-5D-5L). Its impact was no longer significant at 18e24 months
in unmatched and matched cohorts.
Conclusions: The negative impact of chemotherapy on quality-of-life is clinically and statisti-
cally significant at 6 months but resolves by 18 months, which is crucial to inform decision-
making for older patients contemplating chemotherapy.
Trial registration number ISRCTN: 46099296.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Almost half of all breast cancer cases are diagnosed in
patients aged 65 years [1]. Nonetheless, older adults
are under-represented in clinical trials [2]. Moreover,
standard trial end-points may not be appropriate for
older individuals and quality of life (QoL), functional
status and cognition may be as important as chance of
cure [3]. These knowledge gaps contribute to consider-
able variation in treatment in this age group [4].
Curative chemotherapy is associated with a survival
benefit only in patients with node-positive and oestrogen
receptor (ER)enegative disease [5,6]. Older adults have
higher risk of treatment toxicities due to comorbidities
and reduced organ function, while benefits are mitigatedby competing risks [7]. The impact of chemotherapy on
QoL may influence clinicians’ and patients’
perspectives [8].
Therefore, the effect of anticancer treatments on QoL
is essential to inform treatment decisions in this cohort.
The CALGB 49907 study documented better QoL for
patients aged 65 receiving capecitabine versus stan-
dard regimens, but no QoL differences persisted at 1
year [9]. Patients receiving chemotherapy within clinical
trials had better QoL improvements compared with
those treated off study [10]. Nonetheless, prospective
data on QoL for older patients with early breast cancer
(EBC) receiving standard chemotherapy are lacking.
Comorbidities, literacy, symptoms and compliance
may influence patient-reported outcomes [11], but the
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Cancer (EORTC) questionnaires have been validated to
evaluate QoL generically in cancer patients [12] and,
specifically, in older individuals [13] and in those diag-
nosed with breast cancer [14].
We aimed to investigate the impact of chemotherapy
on QoL in real-world EBC patients aged 70 recruited
to the Bridging the Age Gap study [15]. Matching sur-
vival outcomes for the cohort are reported separately.
2. Methods
2.1. Regulatory approval
Ethics approval (IRAS: 12 LO 1808) and research
governance approval were obtained. All patients (or
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Bridging the Age Gap is a prospective multicentre,
observational cohort study. Patients were recruited from
56 UK centres in England and Wales (Table S1).
Eligible patients were women 70 years at diagnosis of
operable invasive breast cancer (tumour-node-metas-
tasis stages: T1-3, plus some operable T4b, N0-1, M0).
Those unsuitable for surgery or with previous EBC
within five years were not eligible.
2.3. Baseline data collection
Patients were recruited at the time of diagnosis and
could participate at three levels: full, partial (no
requirement to complete QoL assessments) or proxy
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chemotherapy analyses. ) Patients who only received palliative
herapy. STROBE, Strengthening the Reporting of Observational
N.M.L. Battisti et al. / European Journal of Cancer 144 (2021) 269e280272Primary tumour characteristics were collected at
baseline. Staging was performed if indicated. Surgery,
radiotherapy and systemic treatment data were also
collected.
Baseline geriatric assessments included comorbidities
(Charlson comorbidity index [CCI]) [16], nutrition
(Abridged Patient Generated Subjective Global Assess-
ment [aPG-SGA]) [17e19], functional status (Eastern
Cooperative Oncology Group Performance status
[ECOG PS], activities of daily living [ADL] [20],
instrumental activities of daily living [IADL]) [21],
cognition (Mini-Mental State Examination [MMSE])
[22] and medications. Patients were classified as high risk
based on 1 of the following criteria: 1) Human
epidermal growth factor receptor type 2 (HER2)-posi-
tive status; 2) ER-negative status; 3) grade III; 4) 1Fig. 2. Mean (95% CI) scores over time points for the chemotherapy ve
C30 scale. CI, confidence interval; EORTC-QLQ, European Organ
Questionnaires; QoL, quality of life.malignant lymph node; 5) recurrence score (RS) 30
(Table S2).
QoL was evaluated using four questionnaires. The
EORTC-QLQ-C30 includes five functional domains
(physical, role, emotional, cognitive and social), nine
symptoms (fatigue, nausea and vomiting, pain, dysp-
noea, insomnia, appetite loss, constipation, diarrhoea
and financial difficulties) and global health status [12].
The EORTC-QLQ-BR23 comprises 23 questions eval-
uating body image, sexual functioning and enjoyment,
future perspective, systemic therapy side-effects, breast
symptoms, arm symptoms and frustration with hair
loss [14]. The EORTC-QLQ-ELD15 contains five scales
(functional independence, relationships with family and
friends, worries about the future, autonomy and burden
of illness) [13]. The EQ-5D-5L was used in this analysisrsus no chemotherapy population measured on the EORTC-QLQ-
isation for Research and Treatment of Cancer Quality-of-Life
Table 1
Baseline postoperative tumour and patient characteristics by receipt of chemotherapy.
Variable Category Chemotherapy No chemotherapy Total
N Z 376 N Z 1144 N Z 1520
Participation level Full 304 (80.9%) 816 (71.3%) 1120 (73.7%)
Partial 68 (18.1%) 284 (24.8%) 352 (23.2%)
Consultee 4 (1.1%) 44 (3.8%) 48 (3.2%)
Main side Right 169 (44.9%) 545 (47.6%) 714 (47.0%)
Left 207 (55.1%) 599 (52.4%) 806 (53.0%)
Tumour size (mm) n 375 1143 1518
Mean (SD) 32.9 (20.7) 29.0 (17.5) 29.9 (18.4)
Median (IQR) 29.0 (21.0, 40.0) 25.0 (18.0, 35.0) 25.0 (18.2, 36.0)
Min, Max 0, 210 0, 155 0, 210
Tumour size (mm) 20 93 (24.7%) 399 (34.9%) 492 (32.4%)
21e50 233 (62.0%) 644 (56.3%) 877 (57.7%)
>50 49 (13.0%) 100 (8.7%) 149 (9.8%)
Unknown 1 (0.3%) 1 (0.1%) 2 (0.1%)
Grade Grade I 2 (0.5%) 77 (6.7%) 79 (5.2%)
Grade II 122 (32.4%) 447 (39.1%) 569 (37.4%)
Grade III 247 (65.7%) 617 (53.9%) 864 (56.8%)
Unknown 5 (1.3%) 3 (0.3%) 8 (0.5%)
Histology Ductal NST 270 (71.8%) 813 (71.1%) 1083 (71.2%)
Lobular carcinoma 52 (13.8%) 110 (9.6%) 162 (10.7%)
Tubular carcinoma 0 (0.0%) 5 (0.4%) 5 (0.3%)
Mucinous carcinoma 1 (0.3%) 13 (1.1%) 14 (0.9%)
Other 29 (7.7%) 97 (8.5%) 126 (8.3%)
Unknown 24 (6.4%) 106 (9.3%) 130 (8.6%)
ER positive? No 132 (35.1%) 240 (21.0%) 372 (24.5%)
Yes 241 (64.1%) 893 (78.1%) 1134 (74.6%)
Unknown 3 (0.8%) 11 (1.0%) 14 (0.9%)
HER2 status Negative 210 (55.9%) 908 (79.4%) 1118 (73.6%)
Inconclusive 3 (0.8%) 7 (0.6%) 10 (0.7%)
Positive 159 (42.3%) 173 (15.1%) 332 (21.8%)
Unknown 4 (1.1%) 56 (4.9%) 60 (3.9%)
Oncotype Dx test performed No 35 (9.3%) 150 (13.1%) 185 (12.2%)
Yes 5 (1.3%) 16 (1.4%) 21 (1.4%)
Not Applicable 252 (67.0%) 434 (37.9%) 686 (45.1%)
Unknown 84 (22.3%) 544 (47.6%) 628 (41.3%)
Breast surgery Wide local excision (non wire localised) 113 (30.1%) 412 (36.0%) 525 (34.5%)
Wire localised wide local excision 43 (11.4%) 150 (13.1%) 193 (12.7%)
Therapeutic mammoplasty/breast reshaping after
WLE
18 (4.8%) 14 (1.2%) 32 (2.1%)
Mastectomy 186 (49.5%) 549 (48.0%) 735 (48.4%)
Mastectomy and reconstruction 12 (3.2%) 11 (1.0%) 23 (1.5%)
Other 4 (1.1%) 8 (0.7%) 12 (0.8%)
Axillary surgery Axillary sample 11 (2.9%) 38 (3.3%) 49 (3.2%)
Axillary clearance 136 (36.2%) 247 (21.6%) 383 (25.2%)
Sentinel lymph node biopsy 200 (53.2%) 725 (63.4%) 925 (60.9%)
Internal mammary node biopsy 0 (0.0%) 1 (0.1%) 1 (0.1%)
No axillary surgery 7 (1.9%) 27 (2.4%) 34 (2.2%)
Unknown 22 (5.9%) 106 (9.3%) 128 (8.4%)
Nodal status pN0-1mi 175 (46.5%) 508 (44.4%) 683 (44.9%)
pN1 117 (31.1%) 494 (43.2%) 611 (40.2%)
pN2 52 (13.8%) 95 (8.3%) 147 (9.7%)
pN3 32 (8.5%) 46 (4.0%) 78 (5.1%)
pNx 0 (0.0%) 1 (0.1%) 1 (0.1%)
Nottingham Prognostic Index n 371 1139 1510
Mean (SD) 5.1 (1.0) 4.7 (0.9) 4.8 (1.0)
Median (IQR) 4.9 (4.4, 5.7) 4.5 (4.3, 5.3) 4.6 (4.3, 5.4)
Min, Max 2.4, 10.2 2.1, 8.1 2.1, 10.2
Age n 376 1144 1520
Mean (SD) 73.65 (3.33) 77.97 (5.19) 76.90 (5.14)
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Table 1 (continued )
Variable Category Chemotherapy No chemotherapy Total
N Z 376 N Z 1144 N Z 1520
age) Mean (SD) 0.79 (1.08) 1.11 (1.38) 1.03 (1.32)
Median (IQR) 0.00 (0.00, 2.00) 1.00 (0.00, 2.00) 1.00 (0.00, 2.00)
Min, Max 0, 6 0, 9 0, 9
Charlson calculated probability n 365 1103 1468
Mean (SD) 0.56 (0.26) 0.43 (0.29) 0.46 (0.29)
Median (IQR) 0.77 (0.21, 0.77) 0.53 (0.21, 0.77) 0.53 (0.21, 0.77)
Min, Max 0, 0.77 0, 0.77 0, 0.77
Number of concurrent medications n 314 1021 1335
Mean (SD) 3.66 (2.51) 4.30 (2.69) 4.15 (2.66)
Median (IQR) 3.00 (2.00, 5.00) 4.00 (2.00, 6.00) 4.00 (2.00, 6.00)
Min, Max 0, 14 0, 18 0, 18
ADL category No dependency 303 (80.6%) 760 (66.4%) 1063 (69.9%)
Mild dependency 33 (8.8%) 146 (12.8%) 179 (11.8%)
Moderate/severe dependency 16 (4.3%) 136 (11.9%) 152 (10.0%)
Unknown 24 (6.4%) 102 (8.9%) 126 (8.3%)
IADL category No dependency 315 (83.8%) 776 (67.8%) 1091 (71.8%)
Mild dependency 26 (6.9%) 124 (10.8%) 150 (9.9%)
Moderate/severe dependency 10 (2.7%) 136 (11.9%) 146 (9.6%)
Unknown 25 (6.6%) 108 (9.4%) 133 (8.7%)
MMSE category Normal function 342 (91.0%) 1004 (87.8%) 1346 (88.6%)
Mild impairment 28 (7.4%) 111 (9.7%) 139 (9.1%)
Moderate impairment 4 (1.1%) 14 (1.2%) 18 (1.2%)
Severe 2 (0.5%) 15 (1.3%) 17 (1.1%)
APG SGA category Low 299 (79.5%) 869 (76.0%) 1168 (76.8%)
Moderate 38 (10.1%) 125 (10.9%) 163 (10.7%)
High 4 (1.1%) 19 (1.7%) 23 (1.5%)
Unknown 35 (9.3%) 131 (11.5%) 166 (10.9%)
ECOG performance status Fully active 296 (78.7%) 740 (64.7%) 1036 (68.2%)
Restricted in physically strenuous activity 59 (15.7%) 284 (24.8%) 343 (22.6%)
Ambulatory and capable of all self-care 3 (0.8%) 43 (3.8%) 46 (3.0%)
Capable of only limited self-care 2 (0.5%) 18 (1.6%) 20 (1.3%)
Unknown 16 (4.3%) 59 (5.2%) 75 (4.9%)
SD, standard deviation; IQR, interquartile range; NST, no special type; ADL, activities of daily living; IADL, instrumental activities of daily living;
MMSE, MinieMental State Examination; APG SGA, Abridged Patient-Generated Subjective Global Assessment; ECOG, Eastern Cooperative
Oncology Group.
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scored separately from 1 to 5.
Patients were followed up at 6 weeks, 6, 12, 18 and 24
months and QoL and side-effects, based on the Com-
mon Terminology Criteria for Adverse Events (CTCAE
v4.0), were assessed at each visit.
2.4. Statistical analyses
Analyses were performed in IBM SPSS statistics version
24 and R version 3.6.3 [24,25]. A p < 0.05 was consid-
ered statistically significant.
The questionnaires were scored according to the
EORTC Scoring Manual (3rd Edition) [13]. Missing
data were managed accordingly. The analysis included
patients with high-risk EBC where QoL questionnaires
were available. The mean difference (95% confidence
interval [CI]) of the domain scores at each time point,
adjusted for baseline scores, was calculated with linear
regression models for high-risk participants. Effect sizes
after analyses of the EORTC-QLQ-C30 were cat-
egorised as either trivial, small, medium or large ac-
cording to pre-specified thresholds for each domain [26].The chemotherapy effect on the global health score
over time for high-risk patients was estimated using a
mixed-effect linear model. The model allowed for time,
treatment, treatmentetime interaction, and baseline
global health status. Differences between the chemo-
therapy and non-chemotherapy groups were derived at
each time point using linear contrasts. The model was
fitted to high-risk patients and to the propensity score-
ematched patients only. For the unmatched analysis the
model also adjusted for age and baseline functionality
scores.
Propensity score matching was performed to
compare the EORTC-QLQ-C30 global health score and
the EQ-5D-5L usual activities score in a matched cohort
receiving chemotherapy versus patients not receiving it.
Logistic regression was used to calculate propensity
scores for treatment allocation in high-risk patients.
These were used to match chemotherapy patients to
those who did not receive chemotherapy based on ADL,
IADL, MMSE, ECOG, aPG-SGA, CCI, number of
medications and age. The ratio and calliper widths of
the propensity scores were chosen based on examination
of propensity score overlaps for several combinations of
N.M.L. Battisti et al. / European Journal of Cancer 144 (2021) 269e280 275ratios and callipers. A 1:3 ratio for chemotherapy to no
chemotherapy and a calliper of 0.25 times the propensity
scores standard deviation was used to optimally match
quality and numbers. Participants were matched on the
Nottingham prognostic index category (good: 3.4,
moderate: 3.5e5.4, poor: >5.4) and HER2 status.3. Results
Between January 2013 and June 2018, 3456 women were
recruited from 56 hospitals in England and Wales, and
3416 included in the analysis. 2811/3416 (82.3%) un-
derwent surgery within 6 months of diagnosis, 1520/
2811 (54.1%) had high-risk EBC and 376/1520 (24.7%)
received chemotherapy (Fig. 1) [27]. The time frames for
treatments received in each cohort are shown in Fig. S1
wherein the slight offset in timing of endocrine therapy
and radiotherapy between the chemotherapy and noFig. 3. Mean (95% CI) scores over time points for the chemotherapy ve
B23 scale. CI, confidence interval; EORTC-QLQ, European Organ
Questionnaires.chemotherapy groups can be seen and should be
considered when interpreting the findings.
Patients had a median age of 76.9 years, had a me-
dian CCI of 1 (range: 0e9), and took a median of four
medications (0e18); 1063 (69.9%) were independent in
their ADLs and 1091 (71.8%) in their IADLs, 1346
(88.6%) had a normal MMSE, 1168 (76.8%) had a low
aPG-SGA score and 1379 (90.7%) had ECOG PS of 0e1
(Table 1).
Chemotherapy data were available for 360 patients:
124 (34.4%) received anthracycline and taxanes, 119
(33.1%) a taxane alone and 116 (32.2%) an anthracycline
alone; one patient received cyclophosphamide, metho-
trexate, fluorouracil. Three-hundred thirty-two patients
(21.8%) had HER2-positive disease: 150 (45.2%)
received chemotherapy plus trastuzumab, 13 (3.9%)
received trastuzumab alone and 9 (2.7%) chemotherapy
alone. EBC was ER-positive in 1134 patients (75.3%),
with 1079 (95.1%) receiving endocrine therapy (Fig. S1).rsus no chemotherapy population measured on the EORTC-QLQ-
isation for Research and Treatment of Cancer Quality-of-Life
Fig. 4. Mean (95% CI) scores over time points for the chemotherapy versus no chemotherapy population measured on the EORTC-QLQ-
ELD15 scale. CI, confidence interval; EORTC-QLQ, European Organisation for Research and Treatment of Cancer Quality-of-Life
Questionnaires.
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with full participation in the protocol (necessary for
completion of QoL questionnaires) and 304/1120
(27.1%) had chemotherapy. Figs. S2eS4 and Tables
S3e5 show completion rates of QoL questionnaires.
3.1. Impact on QoL domains (EORTC-QLQ-C30)
1049/1120 patients (93.7%) completed the global health-
status questions included in the EORTC-QLQ-C30
questionnaire at baseline (Table S6a; Fig. 2). After
adjustment for baseline scores, at 6 weeks the differences
in the mean scores on some EORTC-QLQ-C30 domains
were statistically significant between patients undergo-
ing chemotherapy compared with those of patients not
receiving it, including global health (adjusted meandifference: 2.81, 95% CI: 5.17 to 0.44, p Z 0.020),
social functioning (3.57, CI: 6.71 to 0.43,
p Z 0.026) and constipation (3.43, CI: 0.23 to 6.62,
p Z 0.035). The impact of chemotherapy remained
significant on most domains at 6 months, including
global health which was both statistically and clinically
significant but small (9.20, CI: 11.95 to 6.44,
p < 0.001), physical functioning (medium difference:
8.05, CI: 10.21 to 5.89, p < 0.001), role functioning
(small difference: 17.59, CI: 21.24 to 13.95,
p < 0.001), cognitive functioning (small difference:
5.55, CI: 7.97 to 3.13, p < 0.001), social func-
tioning (large difference: 18.72, CI: 22.17 to 15.27,
p < 0.001), and financial problems (small difference:
3.28, CI: 1.16 to 5.39, p Z 0.002). At 12 months sta-
tistically significant differences persisted in physical
N.M.L. Battisti et al. / European Journal of Cancer 144 (2021) 269e280 277functioning (trivial difference: 2.76, CI 4.95 to
0.57, p Z 0.014), role functioning (trivial difference:
4.41, CI: 8.17 to 0.64, p Z 0.022), social func-
tioning (trivial difference: 3.78, CI: 7.00 to 0.56,
p Z 0.022), diarrhoea (small difference: 4.15, CI: 1.62 to
6.68, p Z 0.001) and financial problems (trivial differ-
ence: 2.50, CI: 0.27 to 4.73, p Z 0.028). Chemotherapy
was no longer impactful in any of these domains at 18
and 24 months.
The analyses were repeated on a propensity
scoreematched subgroup of 410 patients (150 chemo-
therapy, 260 no chemotherapy) with similar findings
(Figs. S5e7; Table S6b).
3.2. Impact on breast cancerespecific QoL domains
(EORTC-QLQ-BR23)
1054/1120 patients (94.1%) completed some or all of the
EORTC-QLQ-BR23 questionnaire at baseline (Fig. 3;Fig. 5. Mean (95% CI) scores over time points for the chemotherapy
scale. The calculated score is a single summary number (index value)
the general population of a country/region and is derived by applying a
as per the EQ-5D-5L User Guide. CI, confidence interval.Table S7). After adjustment for baseline measurements
patients given chemotherapy experienced a significant
decline of some EORTC-QLQ-BR23 mean scores at 6
weeks compared with those not receiving it in future
perspective (adjusted mean difference: 7.20, 95% CI:
10.72 to 3.68, p < 0.001) and systemic therapy side-
effects (3.04, CI: 1.47 to 4.61, p < 0.001). At 6 months,
mean scores were significantly different in future per-
spectives (7.54, CI 11.28 to 3.80, p < 0.001) and
systemic therapy side-effects (16.97, CI: 15.00 to 18.94,
p < 0.001). At 12 months, the mean scores between the
two groups differed in future perspectives (4.96, CI:
8.89 to 1.03, p Z 0.013), systemic therapy side-
effects (3.32, CI: 1.41 to 5.22, p Z 0.001) and the ef-
fect of chemotherapy became significant in arm symp-
toms (4.94, CI: 2.18 to 7.69, p < 0.001). At 18 months,
the differences remained significant in future perspective
(4.97, CI: 9.37 to 0.57, p Z 0.027) and arm
symptoms (3.27, CI: 0.01 to 6.54, p Z 0.049), and at 24versus no chemotherapy population measured on the EQ-5D-5L
which reflects the health state in the context of the preferences of
formula attaching weights to each of the levels in each dimension
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p Z 0.043).
3.3. Impact on older adults-specific QoL domains
(EORTC-QLQ-ELD15)
Some or all of the EORTC-QLQ-ELD15 questionnaire
was completed at baseline by 1048/1120 patients (Table
S8; Fig. 4). At 6 weeks scores were significantly different
between patients given chemotherapy and those not
treated in worries about others (adjusted mean differ-
ence: 5.31, 95% CI: 1.55 to 9.07, p Z 0.006), worries
(4.09, CI: 0.92 to 7.27, p Z 0.011) and burden of illness
(4.68, CI: 1.25 to 8.11, p Z 0.007). These differences
persisted at 6 months (worries about others [6.19, CI:
2.44 to 9.95, p Z 0.001]; worries [4.18, CI: 0.89 to 7.46,
p Z 0.013]; burden of illness [21.60, CI: 17.82 to 25.39,
p < 0.001]); the impact on mobility also became signif-
icant (9.82, CI: 6.87 to 12.78, p < 0.001). At 12 months,
changes remained significant regarding worries about
others (4.47, CI: 0.42 to 8.52, p Z 0.031) and burden of
illness (15.21, CI: 11.30 to 19.12, p < 0.001), which was
the only domain significantly influenced also at 18
months (12.99, CI: 8.81 to 17.17, p < 0.001) and 24
months (8.80, CI: 3.93 to 13.66, p < 0.001).
Maintaining purpose did not differ throughout the
follow-up period, whereas chemotherapy had a positive
impact on family support mean scores at 6 weeks (6.21,
CI: 2.26 to 10.17, pZ 0.002), at 6 months (4.91, CI: 0.26
to 9.56, p Z 0.038) and at 12 months (5.43, CI: 0.39 to
10.46, p Z 0.035).
3.4. Impact on EQ-5D-5L score and questions
Among the high-risk patients, an EQ-5D-5L score was
calculated in 1315 patients (86.5%) at baseline. Health
utilities were similar with estimated mean differences less
than 0.02 units (p > 0.1), whereas the visual analogue
scale measures were significantly worse at 6 months in
patients receiving chemotherapy versus not (adjusted
mean difference: 6.57, 95% CI: 8.74 to 4.40,
p < 0.001). Changes were subsequently no longer sig-
nificant (Table S9; Fig. 5).
A similar pattern on EQ-5D-5L usual activities score
was seen in 520 (118 chemotherapy, 332 no chemo-
therapy) propensity scoreematched patients (Fig. S8).
4. Discussion
This study demonstrates that chemotherapy has both a
clinically and statistically significantly negative impact
at 6e12 months on several QoL domains (physical, role,
cognitive and social functioning, financial problems),
symptom scores (fatigue, nausea, dyspnoea, appetite
loss, constipation, diarrhoea), and perceived global
health. These changes are clinically meaningful andinvolve key domains for this population [28] for whom
even low-grade toxicities may be challenging [29].
Reassuringly, this effect resolves for most items over
18e24 months, which is consistent with previous QoL
data reported in younger cohorts: for example, in 280
EBC patients many domains improved within 12
months after diagnosis, with the exception of cognitive
function and financial problems [30], and similar im-
provements in role functioning were seen in a study of
817 EBC patients [31]. A registry-based analysis docu-
mented better physical functioning, role-physical, role-
emotional and fatigue scales at 15 years in EBC patients
including 46.9% aged 65 [32]. Similarly, 588 EBC pa-
tients enrolled in the Moving Beyond Cancer study had
improved physical and psychosocial functioning after
radical treatment regardless of chemotherapy use [31].
Neuropsychological analyses also confirmed improving
cognitive function during the first four years after
radical therapy for EBC [33,34], although data on
financial impact are limited [30]. The CANTO study
confirmed the transient nature of the impact of chemo-
therapy on QoL in a large population [35]. Nonetheless,
these analyses have either focused on younger patients,
where the risk/benefit ratio is different, or addressed the
impact of breast cancer treatments (and not specifically
of chemotherapy) on QoL in this age group. Our find-
ings are consistent with a previous study in 109 patients
aged 70 or older, of whom 57 received adjuvant doce-
taxel/cyclophosphamide chemotherapy [36].
To our knowledge, this is the largest study to evaluate
the impact of contemporary chemotherapy regimens in
older adults with EBC in real-world patients. QoL is a
meaningful end-point for older patients, who typically
derive less survival benefit and increased toxicities on
systemic anticancer treatments [37,38]. These benefits
need to be carefully balanced with the detrimental
impact on QoL and treatment side-effects [39].
Our analysis included baseline geriatric assessments
characterising patients in relevant health domains for
this age group, such as functional status, comorbidity,
cognition, nutrition and concurrent medications which
may impact QoL. A comprehensive geriatric assessment
can help achieve the required balance between treatment
benefits and side-effects and is recommended by guide-
lines from the American Society of Clinical Oncology,
the National Comprehensive Cancer Network, and the
International Society for Geriatric Oncology [28,40]. In
a randomised study, integrated oncogeriatric care has
recently been shown to improve QoL in older patients
with cancer being considered for systemic anticancer
therapy [41]. Of particular interest was our finding that
in patients 80 the negative impact on QoL does not
resolve, which suggests a lack of resilience in this cohort.
The study has several limitations. Selection bias may
have influenced our findings despite its inclusive entry
criteria and the different levels of participation. The
recruited population was slightly skewed
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UK EBC patient population [42]. Moreover, we did not
include socio-economic factors that might influence
frailty nor the effect of endocrine therapy or radio-
therapy on QoL, owing to multiple confounders to such
an analysis. We did not capture the impact of chemo-
therapy on QoL outcomes beyond 24 months, and
missing data on longitudinal QoL assessments may have
influenced findings. Other factors not measured by our
analysis may also impact on chemotherapy decisions;
therefore, the propensity score matching does not adjust
for all differences between the groups. Furthermore,
some effects of chemotherapy on QoL documented in
our analysis might be statistically significant but not
clinically relevant, although for the majority of domains
clinically meaningful changes are seen at the six-month
time point, which represents the time when most
women would have been on chemotherapy. Finally, it
was not possible to categorise chemotherapy effects on
QoL measured on BR23, ELD15 and EQ-5D-5L do-
mains as thresholds have not been established for these
specific tools, and the latter is a utility scale.
In conclusion, our analysis shows that chemotherapy
has an impact on several QoL domains in older EBC
patients compared with a matched cohort who did not
receive cytotoxics. Nonetheless, these effects are tem-
porary and largely resolve within two years. This is
essential information for older women to use in deci-
sion-making because individualised decisions on treat-
ment options should be based on their values.
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